Cerba Research has conducted ~80 hematological malignancy trials within the last 5 years alone. Download our fact sheet and discover our hematological malignancies trial portfolio with cutting-edge laboratory solutions.

COVID-19 accelerated infectious disease R&D, but timelines and funding are now normalizing. Persistent operational barriers remain, and improved surveillance and communication are needed to enhance vaccine development and trial efficiency.

Our roundtable report from the World Vaccine Congress 2024 discusses the evolving landscape for infectious disease clinical trials, the operational barriers for therapeutics and vaccine development, and why improving epidemiologic surveillance and communication are critical to strengthening site and patient enrollment in clinical trials.

Cerba Research offers specialized HPV SPF10 PCR-detection/typing kits tailored to detect and identify HPV genotypes in vaccine and epidemiology studies. Our HPV vaccine research capabilities ensure comprehensive analysis and accurate identification of relevant genotypes. Take a look at our brochure and discover how our assay excels in analyzing HPV in formalin-fixed-paraffin embedded (FFPE) tissues, facilitating a correlation between histological findings and specific HPV genotypes.

Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone, with 55%+ being solid tumors such as lung, breast, and colorectal cancers. The central and specialty laboratories’ expertise includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), AI in image analysis, and NanoString®. Check our latest fact sheet to learn more about our highlights and capabilities.

Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone. Its experience extends to both solid and liquid tumors and includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), and NanoString®. Check our latest fact sheet to learn more about our highlights and capabilities.

Experience the unparalleled activity of Cerba Research’s Infectious Diseases (ID) therapy sector, boasting a remarkable track record of over 600 executed trials in just the last 5 years.

Discover the extraordinary world of rare diseases, where uniqueness defines the landscape. While these conditions may lack a singular definition, they encompass a myriad of fascinating conditions waiting to be understood and treated.

Cerba Research Montpellier (CRM), a leader in histopathology and part of the Cerba Research group, is revolutionizing solid tumor clinical trials with our cutting-edge NanoString® platforms. Specializing in multiplex immunofluorescence for FFPE tissues, our lab now offers unparalleled transcriptomic and proteomic analysis capabilities.

There are important questions you need to ask yourself and any potential laboratory partner before you start a study including PBMC assays as part of your protocol. When looking at the laboratory partner for your PBMC processing, approaching potential partners with the end in mind is important to ensure that you will be able to generate the data you need in the future.